Jefferies analyst Johnson Wan downgrades XPeng (NYSE:XPEV) from Hold to Underperform and lowers the price target from $18.6 to $4.2.
Decoding 9 Analyst Evaluations For Genmab
Throughout the last three months, 9 analysts have evaluated Genmab (NASDAQ:GMAB), offering a diverse set of opinions from…